Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation?

• Κύριοι συγγραφείς: Sabah Alaklabi (Συγγραφέας), Arya Mariam Roy (Συγγραφέας), Lubna N. Chaudhary (Συγγραφέας), Shipra Gandhi (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Open Exploration Publishing Inc., 2023-12-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Pembrolizumab combined with chemotherapy has been established as the preferred first-line therapy for treating metastatic triple-negative breast cancer (mTNBC) with programmed cell death ligand-1 (PD-L1)-positive disease since its approval for that indication. However, the optimal sequencing of ther...